Kirkland Advises Bristol Myers Squibb on Acquisition of Mirati Therapeutics for up to $5.8 Billion

Advising firms

The announcement does not name individual lawyers.

Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.

Stated terms

Stated value

USD 5.80bn (up to $5.8 billion)

What the figure measures

Total transaction value

Client

Bristol Myers SquibbBuy-side

Counterparties

Mirati Therapeutics (Sell-side)